ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / DRIO / earnings
BEAT (42) PLRZ (34) NEPH (59) TELA (35) ⌘ Pro Terminal →

DarioHealth Corp. (DRIO) Next Earnings Date & Expected ±12.5% Move

$3.00 -9.37% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.94

DarioHealth Corp. (DRIO) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE E • RED ALERT Cap $29.4M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on DRIO Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is DRIO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, DarioHealth Corp. (NASDAQ: DRIO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $3.00 (-9.37% 1D, market cap $29.4M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, DRIO ranks #695 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does DRIO compare to BEAT and PLRZ in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), DRIO carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of 56.6%, and ROIC of -35.0%. By comparison, BEAT (Heartbeam Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $31.0M) and PLRZ (Polyrizon Ltd.) posts a E grade (34/100 RQD, P/E N/A, ROIC -25.1%, cap $26.1M). Among the 5-stock peer group, NEPH leads on earnings multiple (29.8x) while NEPH leads on capital efficiency (18.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for DRIO?
▼

Per DRIO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001533998), DarioHealth Corp. generated $22.4M in revenue (-17.3% YoY), -$41.7M in net income, and -$26.1M in free cash flow against $110.1M in total assets and $30.7M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $2.94 (-1.88%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510033
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Cash (9)Whales (3)SEC (8)Macro (8)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-11.3% Base Target
$16 Bull$3 Base$2 Bear
📬 FREE DRIO RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for DRIO)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (33/100 Composite)
🔍 WHY DRIO SCORES 33/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+9/20 pts (27% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 56.6% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (24% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
41
Grade D$5.54-26.4% Next Q
Q2 (-2Q)
38
Grade E$4.08-14.7% Next Q
Q3 (-1Q)
36
Grade E$3.48-13.8% Next Q
Current
33
Grade E$3.00-8.9% Hist 90D α
Trajectory: D (41) → E (33)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a DRIO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While DRIO currently carries a cautious 33/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.81) and Max Pain ($3.15) forces dealer call-delta covering toward $15.51.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $DRIO• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “DRIO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 33%NO 67%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 30, 2026 (~57 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.38 Expected Swing
$2.62 (-12.5%)Spot $3.00$3.38 (+12.5%)
MODEL EARNINGS SETUP GAUGE

DRIO Quantitative Pre-Earnings Setup: 33/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (33/100)Model Risk Weight (67/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$22.4M-$41.7M-$26.1M56.6%
FY 20242024-12-31$27.0M-$42.7M-$38.7M49.1%
FY 20232023-12-31$0-$59.4M-$30.4M56.6%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring DRIO)

  • ✓Walkthrough of DRIO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
DRIO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -59.73%🛡️ HOLDING TREND SUPPORT
2026-11-03O $3.31H $3.31L $3.00C $3.00VOL 55.5K
RES: $7.51SUP: $2.94SMA50: $5.81SMA200: $7.65
$11.49$9.19$6.89$4.59$2.29RES $7.51SUP $2.94$3.002026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

DRIO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 DRIO Butterfly Map → + Track DRIO →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on DRIO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for DRIO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for DRIO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (DRIO)

Health Care Rank #695 of 1016 ⚔️ BEAT vs DRIO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (DRIO vs. BEAT, PLRZ, NEPH, TELA)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, DarioHealth Corp. (DRIO) ranks #695 by composite RQD confidence (33/100, grade E) and #802 by equity capitalization ($29.4M). Within this direct 5-issuer industry benchmark cohort, NEPH leads on earnings valuation at 29.8x trailing P/E, while NEPH leads on capital efficiency and profitability with 18.9% ROIC and 61.9% gross margin. NEPH currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with DRIO at 33/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
DRIO ACTIVE
DarioHealth Corp.
E 33/100 — 56.6% -35.0% -9.37% $29.4M Benchmark Subject
BEAT
Heartbeam Inc.
D- 42/100 — — -35.0% +2.06% $31.0M /beat-vs-drio →
PLRZ
Polyrizon Ltd.
E 34/100 — — -25.1% +19.40% $26.1M /plrz-vs-drio →
NEPH
Nephros Inc.
C- 59/100 29.8x 61.9% 18.9% -3.06% $34.5M /neph-vs-drio →
TELA
TELA Bio Inc.
D- 35/100 — 67.7% -35.0% -11.95% $36.6M /tela-vs-drio →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001533998

In its most recent audited fiscal period (FY2025, filed 2025-12-31), DarioHealth Corp. (DRIO) reported GAAP revenue of $22.4M (-17.3% vs. FY2024 revenue of $27.0M ) , GAAP net income of -$41.7M, operating cash flow of -$25.9M, and free cash flow of -$26.1M (+32.6% YoY). On the balance sheet, DRIO closed FY2025 with $110.1M in total assets against $30.7M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $22.4M -$41.7M -$25.9M -$26.1M $110.1M $30.7M
FY2024 (FY) 2024-12-31 $27.0M -$42.7M -$38.6M -$38.7M $118.9M $23.5M
FY2023 (FY) 2023-12-31 $0 -$59.4M -$30.4M -$30.4M — —

3. DRIO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is DRIO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, DarioHealth Corp. (NASDAQ: DRIO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $3.00 (-9.37% 1D, market cap $29.4M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, DRIO ranks #695 in composite RQD confidence.

How does DRIO compare to BEAT and PLRZ in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), DRIO carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of 56.6%, and ROIC of -35.0%. By comparison, BEAT (Heartbeam Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $31.0M) and PLRZ (Polyrizon Ltd.) posts a E grade (34/100 RQD, P/E N/A, ROIC -25.1%, cap $26.1M). Among the 5-stock peer group, NEPH leads on earnings multiple (29.8x) while NEPH leads on capital efficiency (18.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for DRIO?

Per DRIO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001533998), DarioHealth Corp. generated $22.4M in revenue (-17.3% YoY), -$41.7M in net income, and -$26.1M in free cash flow against $110.1M in total assets and $30.7M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is DRIO trading relative to its 50-day, 200-day, and 52-week technical levels?

DRIO last traded at $3.00 (-9.37% on volume of 55,534 shares), positioning the stock -48.36% below its 50-day simple moving average ($5.81) and -60.78% below its 200-day simple moving average ($7.65). Across its 52-week range of $3.00 to $14.77, DRIO sits at the 0.0% percentile with a 14-day RSI of 27.3 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($2.62 to $3.38).

DRIO Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is DRIO's next earnings date?

Based on SEC filing cadence, DarioHealth Corp. (DRIO)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is DRIO stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for DRIO, spanning a range between $2.62 and $3.38.

Direct Sub-Reports: DRIO RQD Cockpit DRIO 12M Forecast DRIO Earnings & Move DRIO Dividends & DRIP DRIO Insiders & 13F DRIO Whale Options DRIO Profit Sankey DRIO News & Why
ROARABLE RATING BRIEF • RQD 33/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

DRIO — DarioHealth Corp.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:48:27Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, DRIO carries an RQD Score of 34 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:

  • Fundamental Cash Engine (9 / 20): The rating cites ROIC of -35% and FCF yield of 0%. For a prospective investor, this means the business is not currently generating returns on invested capital or free cash flow to support its valuation from operations; any upside case must rest on a turnaround not evidenced in the reported figures.
  • Whale 13F Flow (3 / 20): Institutional accumulation and options positioning scored lowest among the pillars. The holder data for this section is not available in source data, so the low score reflects the rating's assessment rather than an itemized holdings table.
  • Insider Conviction (5 / 20): SEC Form 4 and Congressional PTR cluster flow scored weakly. Insider signaling is therefore not a source of support in this rating.
  • Macro Regime Fit (9 / 20): Beta of 1.0 and the rating's sector-sensitivity assessment place the stock in a neutral-to-moderate macro exposure band, but without a strong regime tailwind.
  • Forensic Balance Sheet (8 / 20): Altman Z of 2.5, Piotroski F of 5 out of 9, and Debt/Equity of 0.45 combine into a moderate-to-weak forensic profile. Solvency is not the primary concern; the operating losses are.

Taken together, the pillars indicate that the dominant risk is operational cash burn rather than leverage. Valuation tradeoffs are sharp: at a market capitalization of $32.4M against reported net losses in every listed period, the equity is priced as a speculative option on a future operating turnaround. The upside driver is a credible path to positive operating income; the downside is continued cash consumption and dilution risk not resolved by the source data.

Business

DarioHealth Corp. is a NASDAQ-listed issuer classified in the Health Care sector and Medical/Dental Instruments industry, per the profile section. The source data does not describe its specific products, customer base, or revenue model beyond the sector classification. Reported revenue was $22.4M in FY 2025, per the SEC financials. Gross margin is 56.6% per the market data, but the source data does not detail how the company generates this revenue. Further business description is not available in source data.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$22.4M$-36.7M$-41.7MN/A$-26.1M$21.8M$30.7M
FY 2024$27.0M$-57.7M$-42.7MN/A$-38.7M$27.8M$23.5M
FY 2023$0.0M$-56.2M$-59.4MN/A$-30.4MN/AN/A

Per the SEC financials, the company reported operating and net losses in all three periods, with revenue declining from $27.0M in FY 2024 to $22.4M in FY 2025. Per the market data, operating margin and net margin are each -60% and ROIC is -35%. Per the Roarable RQD rating, Altman Z-Score is 2.5, Piotroski F-Score is 5 out of 9, and Debt/Equity is 0.45. Reported debt rose from $23.5M in FY 2024 to $30.7M in FY 2025 while cash fell from $27.8M to $21.8M.

Recent Catalysts & News Wire Analysis

Per the recent news and catalysts section, the most recent items include a Yahoo Finance report on a fair value cut citing growth and revenue risks, a TradingView estimates page, and a Stock Titan notice of an 8:30 a.m. call covering third-quarter results before markets open Nov. 12. Multiple items reference a BTIG initiation with a Buy rating and a $6 price target. Lights are marked GREEN on the Yahoo Finance and Investing.com items (both labeled CATALYST) and YELLOW on the remaining items (labeled MARKET WIRE). The fair-value-cut headline is the primary risk watch item, while the upcoming third-quarter results call is a near-term event. The Butterfly supply-chain graph reports no supply chain and no proprietary signals.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore not available in source data. The only sector context provided is the Health Care sector and Medical/Dental Instruments industry classification. A prospective investor should note that the absence of mapped links means ripple effects from suppliers, customers, or peers cannot be assessed from the provided sources.

Analyst View & Smart Money Ownership

Analyst data is not available in source data. Holder data is not available in source data, including any SEC Form 4, 13F, or Congressional trades. The Roarable RQD rating's low insider and whale-flow pillar scores reflect that signal weakness, but no itemized trades are provided.

Open Questions

  • What are the company's specific products, customers, and revenue drivers, given that the source data gives only a sector classification?
  • What drove the revenue decline from $27.0M to $22.4M between FY 2024 and FY 2025, and what does the fair-value-cut report attribute it to?
  • What is the path to positive operating income, given operating losses of $-36.7M in FY 2025 and $-57.7M in FY 2024?
  • How will the company fund operations given FCF of $-26.1M against cash of $21.8M, and is further equity dilution anticipated?
  • What are the third-quarter results expected on Nov. 12, and how do they compare to the source data's trend?

DRIO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for DarioHealth Corp. (DRIO) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to DRIO Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

DRIO Bull vs. Bear Conversation Board — What's Your Call at $3.00?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON DRIO 🐻 67% BEARISH CONVICTION
1. Pick Your Side on DRIO:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $2.91 (-12.1%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is DRIO (E • RQD 34/100) a Buy at $3.31?

Welcome to the DRIO (DarioHealth Corp.) Roar Pit. Current RQD Composite is 34/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RI RiskArb_Desk Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $2.75 (-16.9%)
Spot @ $3.31

Pump the brakes on DRIO — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on DRIO, but look at what you are paying: current EV/EBITDA multiples with 56.6% gross margins. Unless DarioHealth Corp. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

CA CashFlowKing Verified K Arena Trader 🐂 BULLISH 🎯 Target: $3.81 (+15.1%)
Spot @ $3.31

DRIO cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on DRIO, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $3.31 (52-wk range $3.00 - $14.77), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%